Skip to Main Content

Paper Details

Preserved SARS-CoV-2 Vaccine Cell-Mediated Immunogenicity in Patients With Inflammatory Bowel Disease on Immune-Modulating Therapies.
Clin Transl Gastroenterol
6
2022
IBD, IBDs, Inflammatory Bowel Disease, Patients, SARS, SARS-CoV, SARS-CoV-2, inflammatory bowel diseases, infliximab, mRNA, patients, thiopurine
Author NameAffiliation
Brigid S BolandUniversity of California
Brigid S BolandUniversity of California
Parambir S DulaiUniversity of California
Siddharth SinghUniversity of California
Nghia H NguyenUniversity of California
Alessandro SetteCenter for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology
Alessandro SetteUniversity of California
Alessandro SetteCenter for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology
Alessandro SetteUniversity of California
John T ChangUniversity of California
John T ChangUniversity of California
  • 1 - 11

Datasets

Release 1.2